OcuTerra is developing a novel eye drop, OTT166, designed to treat diabetic eye disease. This first-in-class, highly disruptive treatment has the potential to treat diabetic eye disease earlier and more efficiently, with established clinical data showing safety and demonstrating biological activity

Biotechnology

OcuTerra Therapeutics

OcuTerra Therapeutics' headquarters in Boston, MA, United States

Susannah Sinozich

David J. Tanzer

Bill Steinkrauss

Barbara Ryan

William H. Koster

Robin Steele

David S. Boyer

Robert Ruffolo

Peter Kaiser

Paul Karpecki

Brent Saunders

Jeffrey S. Heier

Sheri Rowen

Richard Lindstrom

Description

People (2)

William H. Koster

Bill Steinkrauss

Jobs